Should I obtain comprehensive molecular profiling before initiating amivantamab (amivantamab) in a patient with stage IV EGFR‑mutant lung adenocarcinoma who has progressed on gefitinib, osimertinib, pemetrexed, and carboplatin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, you should obtain comprehensive molecular profiling before initiating amivantamab in this patient who has progressed on osimertinib.

Tissue rebiopsy with comprehensive DNA/RNA-based next-generation sequencing (NGS) is strongly recommended when feasible to identify actionable resistance mechanisms and guide optimal treatment selection 1. This is critical because the resistance landscape after osimertinib is highly heterogeneous, and identifying specific alterations can significantly impact treatment decisions and outcomes.

Why Molecular Profiling is Essential

Identifying Targetable Resistance Mechanisms

After osimertinib progression, multiple resistance mechanisms emerge that require different therapeutic approaches:

  • MET amplification occurs in up to 24% of patients progressing on osimertinib and represents the most common off-target resistance mechanism 1. While amivantamab targets both EGFR and MET, confirming MET amplification provides additional rationale for its use and may influence combination strategies.

  • Other EGFR mutations beyond the original sensitizing mutation (such as C797X, G724S, L718Q, L792H, G769R) can emerge after osimertinib 1. These may guide clinical trial enrollment or alternative treatment approaches.

  • Actionable bypass pathways including ERBB2 amplification, BRAF mutations, MET exon 14 skipping, and oncogenic fusions (RET, ALK, ROS1, BRAF, FGFR3, NTRK1) can be identified and potentially targeted 1.

Detecting Histologic Transformation

Approximately 15% of patients develop histologic transformation at progression, most commonly to small cell lung cancer (SCLC) 1. This fundamentally changes treatment strategy, as transformed SCLC responds to platinum/etoposide chemotherapy rather than continued EGFR-directed therapy. Tissue biopsy is the only way to detect this transformation.

Optimal Testing Approach

Preferred Method

DNA/RNA-based NGS using comprehensive gene panels should be the preferred approach given the heterogeneity of resistance patterns 1. DNA-based NGS alone can miss some fusions, so RNA-based testing is recommended for complete fusion detection 1.

If Tissue Biopsy is Not Feasible

Circulating tumor DNA (ctDNA) testing represents a viable alternative when tissue sampling cannot be performed 1. However, recognize its limitations:

  • Cannot capture histologic transformation
  • Limited sensitivity for amplifications and fusions
  • Approximately 25% of patients are "non-shedders" with insufficient circulating DNA 1

Clinical Decision Algorithm

Before initiating amivantamab:

  1. Attempt tissue rebiopsy at a site of progressive disease

    • Perform histologic evaluation for transformation
    • Send for comprehensive DNA/RNA-based NGS panel

  2. If tissue biopsy not feasible:

    • Obtain liquid biopsy (ctDNA testing)
    • Use assays with high analytical sensitivity
    • Interpret negative results cautiously

  3. Based on results:

    • No targetable alterations identified → Proceed with amivantamab plus carboplatin/pemetrexed as recommended 2
    • MET amplification confirmed → Strong rationale for amivantamab (dual EGFR/MET targeting)
    • Other targetable alterations → Consider alternative targeted therapies or clinical trials
    • SCLC transformation → Switch to platinum/etoposide chemotherapy
    • Squamous transformation → Consider histology-specific treatments

Important Caveats

Don't Delay Treatment Unnecessarily

While molecular profiling is strongly recommended, do not delay treatment initiation if the patient has rapidly progressive, symptomatic disease and tissue cannot be obtained promptly. In such cases, proceed with amivantamab plus chemotherapy based on the known EGFR mutation status, as this regimen showed significant benefit in the MARIPOSA-2 trial regardless of specific resistance mechanisms 2.

Assay Selection Matters

For patients on osimertinib specifically, anecdotal evidence suggests FISH may detect higher rates of MET amplification than NGS-based methods 1. Consider both approaches if MET amplification is suspected but not detected on NGS.

The Evidence Supporting Amivantamab

The 2024 ASCO guidelines provide a strong recommendation for platinum-based chemotherapy with or without amivantamab after osimertinib progression 2. The MARIPOSA-2 study demonstrated that amivantamab plus chemotherapy significantly improved progression-free survival (6.3 months vs 4.2 months, HR 0.48) and objective response rate (64% vs 36%) compared to chemotherapy alone 2.

However, this benefit was demonstrated across the study population, and molecular profiling helps optimize individual patient selection and may identify alternative superior options for specific resistance mechanisms.

References

Related Questions

In a 54‑year‑old woman with EGFR‑mutated non‑small cell lung cancer who progressed on adjuvant osimertinib with hepatic metastases, what is the role of amivantamab?
What is the mechanism of action, approved indication, common adverse effects, and their management for amivantamab?
What post‑infusion supportive medications and subsequent therapy are recommended after completing amivantamab (EGFR/MET bispecific antibody) treatment?
Does amivantamab (RYBREVANT) cross the blood‑brain barrier?
What are the adverse effects of amivantamab (Rybrevant)?
A patient with recent HIV exposure who has completed the initial post‑exposure prophylaxis work‑up now presents with fever; which laboratory tests should be ordered to evaluate possible HIV infection?
Can moxifloxacin be used to treat plague in an otherwise healthy adult, and what is the recommended dosing regimen?
In a patient with known ischemic cardiomyopathy and heart failure with reduced ejection fraction who has experienced new nighttime chest pain for several days but is now asymptomatic, can aspirin be added to his clopidogrel regimen while awaiting laboratory results?
What is the appropriate next step in managing a 30‑year‑old female with acute diarrhea who vomited after receiving oral loperamide while on intravenous fluids?
Should aspirin and clopidogrel be held in a patient on dual antiplatelet therapy after a transient ischemic attack who presents with bright red rectal bleeding?
In a patient with mildly hyperactive bowel sounds and no abdominal distension, what is the appropriate management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.